Search DIAN Data Resource Requests

Title:Cerebral Amyloid Angiopathy due to APP mutation: Clinicopathological manifestations and brain imaging findings

Date of Request:1/7/2014

Status:IP

ID:DIAN-D1401

Aim 1:1. To investigate the clinicopathological features of cerebral amyloid angiopathy in an HCHWA-Dutch Type kindred

Aim 2:2. To investigate the CSF and Blood biomarkers related to Alzheimer’s disease in the APP Dutch Type mutation carriers and non-carriers

Aim 3:3. To compare the mutation carriers and non-carriers' on MRI, FDG and PiB PET imaging results

Aim 44. To compare the mutation carriers and non-carriers on clinical, cognitive and personality measures

Title:Brain and cognitive reserve capacities in DIAN participants

Date of Request:1/8/2014

Status:IP

ID:DIAN-D1402

Aim 1:1. To examine whether DIAN participants differ in terms of their brain reserve (as indicated by brain volume, cortical thickness, white matter hyper intensities etc.) and cognitive reserve (as indicated by education years and Hollingshead Index of Social Position).

Aim 2:2. 2. To examine if cognitive and brain reserves indices are associated with delay in clinical manifestation of the AD.

Aim 3:3. 3. To Compare these groups on blood and CSF biomarkers and imaging results at baseline and follow ups

Aim 44. 4. To investigate whether higher baseline cognitive function delays the age at onset?

Title:Vital signs in the different stages of dominantly inherited Alzheimer`s disease

Date of Request:2/17/2014

Status:A

ID:DIAN-D1403

Aim 1:To compare vital signs between mutation carriers (MC) and non-mutation carriers (NMC) at different clinical stages as assessed with Clinical Dementia Rating (CDR) scale.

Aim 2:To compare vital signs between MC and NMC as a function of estimated years to onset (EYO).

Aim 3:To determine the association between vital signs and clinical parameters (age, gender, EYO, GDS), psychometric parameters (MMSE, CDR global, CDR sum of boxes, Logical Memory, delayed recall), biochemical biomarkers (CSF levels of Abeta 1-42 and tau) and neuro-imaging biomarkers (PiB-PET SUVR).

Title:QSM analysis of susceptibility weighted imaging data

Date of Request:3/26/2014

Status:A

ID:DIAN-D1404

Aim 1:development of quantitative susceptibility mapping as a novel biomarker in preclinical AD

Aim 2:To examine whether early basal ganglia PIB ligand uptake is associated with altered iron levels

Title:Understanding attitudes toward clinical trials among persons at risk for autosomal dominant Alzheimer's disease

Date of Request:6/3/2014

Status:IP

ID:DIAN-D1405

Aim 1:To characterize the differences in DIAN participants who do and do not want to know their genetic status

Aim 2:To examine the proportion of at-risk individuals who would change their mind whether to undergo genetic testing in the setting of a clinical trial and to characterize differences in these participants, compared to those continue to refuse genetic testing

Aim 3:To assess the effects of the possibility of receiving placebo and varying drug/placebo ratios on persons’ desire to undergo genetic testing and participate in a clinical trial

Aim 4To assess the effects of the possibility of an open-label extension on persons’ desire to undergo genetic testing and participate in a clinical trial

Title:Phenotypic Variability in Autosomal Dominant Alzheimer's Disease

Date of Request:6/30/2014

Status:IP

ID:DIAN-D1406

Aim 1:Establish correlations between specific ADAD mutation types and clinical presentation, taking into account the familial genetic background.

Aim 2:Aim 2. Identify groups of mutations which have similarities in both clinical phenotype and biomarker and imaging profiles.

Title:Patterns and mechanisms of brain atrophy in healthy aging and dementia

Date of Request:8/13/2014

Status:IP

ID:DIAN-D1407

Aim 1:To test the relationship between structural brain measures, amyloid levels and cognitive function

Title:Fronto-thalamic effective connectivity in familial Alzheimer?s disease

Date of Request:9/18/2014

ID:DIAN-D1409

Aim 1:To investigate effective connectivity of three anatomically defined fronto-thalamic circuits in the DIAN baseline data. Specifically, we propose to use stochastic dynamic causal modelling (sDCM) of regional time-courses extracted from resting-state functional MRI (rs-fMRI).

Aim 2:To determine whether abnormalities of effective connectivity within these neural circuits can be detected during presymptomatic or early-stage familial Alzheimers disease (FAD), and to evaluate the utility of different metrics as potential imaging biomarkers.

Aim 3:To explore the (cross-sectional) relationships between the imaging metrics and measures of cognitive function and behaviour.

Title:Growth factors, neuroinflammation, exercise, and brain integrity

Date of Request:9/18/2014

ID:DIAN-D1408

Aim 1:Determine how inflammation gene risk variants influence inflammation marker TNFα, and how genes and TNFα together relate to brain volume.

Aim 2:Show how growth factors and homocysteine relate ROI (hippocampus, cingulate gyrus, prefrontal cortex) volumes.

Aim 3:Determine (1) how our ROI volumes relate to measures of exercise (2) how growth factors and TNFα modulate any relationship between exercise and these ROIs.

Aim 4Evaluate how baseline serum measures and candidate risk genes together predict changes in ROI volume and cognition over 2 years.

Title:TBM-SyN in DIAN

Date of Request:10/2/2014

ID:DIAN-D1410

Aim 1:Measure atrophy rates in DIAN subjects with a new algorithm called TBM-SyN

Aim 2:Test hypothesis that sample size estimates will be superior with TBM-SyN than with longitudinal freesurfer